Salarius Pharmaceuticals, Inc. confirmed its Nasdaq listing status after incorrect reports claimed it was delisted, which occurred on November 13, 2025. The company remains compliant with Nasdaq's listing requirements following its merger with Decoy Therapeutics, Inc.